|
Characteristic
|
Number of patients (%)
|
|---|
|
Sex
|
|
Male
|
54 (73.0)
|
|
Female
|
20 (27.0)
|
|
Stage of primary tumora
|
|
I
|
17 (23.0)
|
|
II
|
16 (21.6)
|
|
III
|
34 (45.9)
|
|
Unknown
|
7 (9.5)
|
|
Histology
|
|
Squamous cell carcinoma
|
18 (24.3)
|
|
Adenocarcinoma
|
41 (55.4)
|
|
Lymphoepithelioma-like carcinoma
|
10 (13.3)
|
|
Others
|
5 (6.8)
|
|
EGFR status
|
|
Mutation
|
14 (18.9)
|
|
Wild-type
|
37 (50.0)
|
|
Unknown
|
23 (31.1)
|
|
Recurrence site
|
|
Stump
|
8 (10.8)
|
|
Regional lymph nodes
|
56 (75.7)
|
|
Ipsilateral lung
|
6 (8.1)
|
|
Both stump and regional lymph nodes
|
3 (4.0)
|
|
Both regional lymph nodes and ipsilateral lung
|
1 (1.4)
|
|
Concurrent chemotherapy
|
|
Yes
|
59 (79.7)
|
|
No
|
15 (20.3)
|
|
Radiation technique
|
|
3D-CRT
|
5 (6.8)
|
|
IMRT
|
62 (83.8)
|
|
SBRT
|
7 (9.4)
|
-
NSCLC non-small cell lung cancer, EGFR epidermal growth factor receptor, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, SBRT stereotactic body radiotherapy
-
aThe 7th edition of the American Joint Committee on Cancer (AJCC) staging system was used
